Found: 53
Select item for more details and to access through your institution.
Influence of the major histocompatibility complex on age at onset of chronic lymphoid leukaemia.
- Published in:
- International Journal of Cancer, 1996, v. 65, n. 2, p. 134, doi. 10.1002/(SICI)1097-0215(19960117)65:2<134::AID-IJC2>3.0.CO;2-#
- By:
- Publication type:
- Article
The Challenge of AML in Older Patients.
- Published in:
- Mediterranean Journal of Hematology & Infectious Diseases, 2013, v. 5, n. 1, p. 1, doi. 10.4084/MJHID.2013.038
- By:
- Publication type:
- Article
A randomised evaluation of low‐dose cytosine arabinoside plus lenalidomide versus single‐agent low‐dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI‐1 trial.
- Published in:
- British Journal of Haematology, 2024, v. 204, n. 3, p. 871, doi. 10.1111/bjh.19220
- By:
- Publication type:
- Article
A randomised evaluation of low‐dose Ara‐C plus pegylated recombinant arginase BCT‐100 versus low dose Ara‐C in older unfit patients with acute myeloid leukaemia: Results from the LI‐1 trial.
- Published in:
- British Journal of Haematology, 2023, v. 200, n. 5, p. 573, doi. 10.1111/bjh.18560
- By:
- Publication type:
- Article
A randomised comparison of FLAG‐Ida versus daunorubicin combined with clofarabine in relapsed or refractory acute myeloid leukaemia: Results from the UK NCRI AML17 trial.
- Published in:
- British Journal of Haematology, 2022, v. 198, n. 3, p. 528, doi. 10.1111/bjh.18195
- By:
- Publication type:
- Article
Therapy for isocitrate dehydrogenase 2 (IDH2)<sup>R172</sup>‐mutant acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 6, p. 1348, doi. 10.1111/bjh.17981
- By:
- Publication type:
- Article
Gemtuzumab ozogamicin in (KMT2A)‐rearranged adult acute myeloid leukaemia (AML) in the UK Medical Research Council AML15 and AML16 trials.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 5, p. e50, doi. 10.1111/bjh.17943
- By:
- Publication type:
- Article
Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 5, p. 832, doi. 10.1111/bjh.17336
- By:
- Publication type:
- Article
Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3‐ITD acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2020, v. 191, n. 2, p. 231, doi. 10.1111/bjh.16665
- By:
- Publication type:
- Article
The clinical impact of mutant DNMT3A R882 variant allele frequency in acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 3, p. e81, doi. 10.1111/bjh.16486
- By:
- Publication type:
- Article
Analysis of the clinical impact of NPM1 mutant allele burden in a large cohort of younger adult patients with acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 6, p. 852, doi. 10.1111/bjh.16239
- By:
- Publication type:
- Article
Twenty five years of UK trials in acute myeloid leukaemia: what have we learned?
- Published in:
- British Journal of Haematology, 2020, v. 188, n. 1, p. 86, doi. 10.1111/bjh.16359
- By:
- Publication type:
- Article
The value of molecular stratification for CEBPA<sup>DM</sup> and NPM1<sup>MUT</sup> FLT3<sup>WT</sup> genotypes in older patients with acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2016, v. 172, n. 4, p. 573, doi. 10.1111/bjh.13873
- By:
- Publication type:
- Article
An immunophenotypic pre-treatment predictor for poor response to induction chemotherapy in older acute myeloid leukaemia patients: blood frequency of CD34<sup>+</sup> CD38<sup>low</sup> blasts.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 1, p. 80, doi. 10.1111/bjh.13398
- By:
- Publication type:
- Article
Who is an 'older' patient with acute myeloid leukaemia ( AML)? An investigation of two NCRI/ AML trials.
- Published in:
- British Journal of Haematology, 2014, v. 165, n. 1, p. 147, doi. 10.1111/bjh.12705
- By:
- Publication type:
- Article
GATA2 mutations in sporadic and familial acute myeloid leukaemia patients with CEBPA mutations.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 5, p. 701, doi. 10.1111/bjh.12317
- By:
- Publication type:
- Article
Tris(8-hydroxyquinolinato)gallium(III)-Loaded Copolymer Micelles as Cytotoxic Nanoconstructs for Cosolvent-Free Organometallic Drug Delivery.
- Published in:
- Small, 2011, v. 7, n. 12, p. 1635, doi. 10.1002/smll.201100405
- By:
- Publication type:
- Article
Getting to the Heart of Improving Outcomes for Patients With Acute Promyelocytic Leukemia.
- Published in:
- 2012
- By:
- Publication type:
- Opinion
Treatment of Acute Leukaemias – New Directions for Clinical Research.
- Published in:
- 2003
- By:
- Publication type:
- Book Review
The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro.
- Published in:
- European Journal of Haematology, 2000, v. 64, n. 4, p. 211, doi. 10.1034/j.1600-0609.2000.90139.x
- By:
- Publication type:
- Article
Treatment of acute myeloid leukaemia.
- Published in:
- Clinical Medicine, 2013, v. 13, p. s58, doi. 10.7861/clinmedicine.13-6-s58
- By:
- Publication type:
- Article
Who should be transplanted in first remission of acute myeloid leukaemia?
- Published in:
- 2011
- By:
- Publication type:
- journal article
Progress in the Treatment of Acute Myeloid Leukemia.
- Published in:
- Cancer (0008543X), 2007, v. 110, n. 9, p. 1900, doi. 10.1002/cncr.23000
- By:
- Publication type:
- Article
A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment.
- Published in:
- 2007
- By:
- Publication type:
- journal article
A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatmentSee related Editorial on pages 000–000, this issue.The following investigators entered patients in this trial: Aberdeen Royal Infirmary: Dr. D. J. Culligan and Dr. J. Tighe; Altnagelvin Area Hospital: Dr. M. F. Ryan; Arrowe Park Hospital: Dr. D. W. Galvani; Barnet General Hospital: Dr. A. Virchis; Belfast City Hospital: Dr. R. J. G. Cuthbert, Dr. M. F. McMullin, and Dr. T. C. M. Morris; Bradford Royal Infirmary: Dr. L. A. Parapia and Dr. A. T. Williams; Bristol Royal Infirmary: Dr. G. L. Scott and Dr. G. R. Standen; Broadgreen Hospital: Dr. P. Chu; Canterbury Health Laboratories: Dr. W. N. Patton; Central Middlesex Hospital: Dr. K. Ryan; Christchurch Hospital: Dr. R. L. Spearing; Christie Hospital: Dr. R. Chopra; City Hospital National Health Service (NHS) Trust: Dr. D. Barefor
- Published in:
- Cancer (0008543X), 2007, v. 109, n. 6, p. 1114
- By:
- Publication type:
- Article
Severe adverse impact on sexual functioning and fertility of bone marrow transplantation, either allogeneic or autologous, compared with consolidation chemotherapy alone: analysis of the MRC AML 10 trial.
- Published in:
- 1999
- By:
- Publication type:
- journal article
Should We GO to FLAG-Ida?.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2018, v. 18, p. S56, doi. 10.1016/j.clml.2018.06.056
- By:
- Publication type:
- Article
Treatment of Older Patients With Newly Diagnosed AML Unfit for Traditional Therapy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
AML: The Next Question.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. S131, doi. 10.1016/j.clml.2017.08.061
- By:
- Publication type:
- Article
CD34-related coexpression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age.
- Published in:
- 2007
- By:
- Publication type:
- journal article
Normal Hematopoietic Progenitor Subsets Have Distinct Reactive Oxygen Species, BCL2 and Cell-Cycle Profiles That Are Decoupled from Maturation in Acute Myeloid Leukemia.
- Published in:
- PLoS ONE, 2016, v. 11, n. 9, p. 1, doi. 10.1371/journal.pone.0163291
- By:
- Publication type:
- Article
Does BCR/ ABL1 positive Acute Myeloid Leukaemia Exist?
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 4, p. 541, doi. 10.1111/bjh.12301
- By:
- Publication type:
- Article
The HSP90 inhibitor NVP- AUY922- AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 1, p. 57, doi. 10.1111/bjh.12215
- By:
- Publication type:
- Article
Utility of a clinical risk score to identify high-risk patients with de novo acute myeloid leukaemia in first remission after high-dose cytarabine (Hi DAC) based induction chemotherapy.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 6, p. 861, doi. 10.1111/bjh.12178
- By:
- Publication type:
- Article
Prognostic and therapeutic relevance of c- FLIP in acute myeloid leukaemia.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 2, p. 188, doi. 10.1111/bjh.12108
- By:
- Publication type:
- Article
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
- Published in:
- British Journal of Haematology, 2012, v. 158, n. 4, p. 519, doi. 10.1111/j.1365-2141.2012.09165.x
- By:
- Publication type:
- Article
Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party
- Published in:
- British Journal of Haematology, 2009, v. 146, n. 1, p. 54, doi. 10.1111/j.1365-2141.2009.07710.x
- By:
- Publication type:
- Article
Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials.
- Published in:
- British Journal of Haematology, 2009, v. 145, n. 5, p. 598, doi. 10.1111/j.1365-2141.2009.07663.x
- By:
- Publication type:
- Article
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
- Published in:
- British Journal of Haematology, 2009, v. 145, n. 3, p. 318, doi. 10.1111/j.1365-2141.2009.07604.x
- By:
- Publication type:
- Article
Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial.
- Published in:
- British Journal of Haematology, 2007, v. 136, n. 1, p. 96, doi. 10.1111/j.1365-2141.2006.06403.x
- By:
- Publication type:
- Article
The tumour antigens RAGE-1 and MGEA6 are expressed more frequently in the less lineage restricted subgroups of presentation acute myeloid leukaemia.
- Published in:
- 2006
- By:
- Publication type:
- Letter
Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
- Published in:
- 2004
- By:
- Publication type:
- Letter
correspondence Long-term survival of myelodysplastic patients with macrocytosis.
- Published in:
- 2004
- By:
- Publication type:
- Letter
Prognosis of myelodysplasic patients: non-parametric multiple regression analysis of populations stratified by mean corpuscular volume and marrow myeloblast number.
- Published in:
- British Journal of Haematology, 2002, v. 119, n. 1, p. 87, doi. 10.1046/j.1365-2141.2002.03783.x
- By:
- Publication type:
- Article
Current Controversies: Which Patients With Acute Myeloid Leukaemia Should Receive A Bone Marrow Transplantation? – An Adult Treater's View.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 2, p. 357, doi. 10.1046/j.1365-2141.2002.03698.x
- By:
- Publication type:
- Article
The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial.
- Published in:
- British Journal of Haematology, 2002, v. 118, n. 2, p. 385, doi. 10.1046/j.1365-2141.2002.03724.x
- By:
- Publication type:
- Article
Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial.
- Published in:
- British Journal of Haematology, 2001, v. 113, n. 3, p. 713, doi. 10.1046/j.1365-2141.2001.02785.x
- By:
- Publication type:
- Article
The Emerging Role of Targeted Therapy for Hematologic Malignancies: Update on Bortezomib and Tipifarnib.
- Published in:
- Oncologist, 2007, v. 12, n. 3, p. 281, doi. 10.1634/theoncologist.12-3-281
- By:
- Publication type:
- Article
Thymus-leukaemia antigens: The haemochromatosis gene product?
- Published in:
- Immunology & Cell Biology, 1994, v. 72, n. 5, p. 435, doi. 10.1038/icb.1994.64
- By:
- Publication type:
- Article
Homozygous MHC Genotypes and Longevity.
- Published in:
- Human Heredity, 1994, v. 44, n. 5, p. 271, doi. 10.1159/000154229
- By:
- Publication type:
- Article